Updates in Treatment and Management of Chemotherapy-induced Myelosuppression

Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.

Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.